AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)

Paresh Vyas, Naval Daver, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, David Sallman

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)'. Together they form a unique fingerprint.

Medicine & Life Sciences